Biohaven's BHV-1530 shows responses in 6 of 10 evaluable patients in Phase 1 cancer trial
BHVN•Biohaven reported responses in 6 of 10 evaluable patients in a Phase 1 trial of BHV-1530 for cancers with FGFR3 alterations. A pivotal trial could begin as early as the first half of 2027, initially targeting urothelial cancer.
1. Phase 1 results
Biohaven presented Phase 1 results for BHV-1530 at ENA 2026, showing responses in FGFR3-altered urothelial and head and neck cancers. Some responders had previously treated cancers that had progressed, and all responders remained on treatment at the data cutoff, with some treated for more than six months. The drug was well tolerated, with no dose-limiting toxicities or treatment-related serious adverse events or deaths.
2. Potential pivotal trial
Following discussions with the FDA, a pivotal trial could begin as early as the first half of 2027, initially targeting urothelial cancer for potential accelerated approval.




